Table 2 Survival analysis

Age: (yr)

≤ 60 yr

15 (13.3%)

0.617

0.822

0.374-1.808

0.627

> 60 yr

15 (20.0%)

Gender: n(%)

Male

27 (18.5%)

0.725

0.809

0.238-2.748

0.734

Female

3 (0)

CEA

Normal

23 (13.0%)

0.499

0.716

0.265-1.936

0.497

Increased

7 (28.6%)

AFP

Normal

24 (16.7%)

0.728

1.185

0.443-3.172

0.736

Increased

6 (16.7%)

CA19-9

Normal

22 (13.6%)

0.527

0.748

0.297-1.886

0.538

Increased

8 (25.0%)

Ascites

Yes

7 (17.4%)

0.793

1.127

0.449-2.833

0.799

No

23 (14.3%)

Primary tumor size

< 5cm

18 (22.2%)

0.984

1.008

0.454-2.236

0.985

≥ 5cm

12 (8.3%)

Number of liver metastasis

Single

22 (22.2%)

*0.028

2.456

1.048-5.756

*0.039

Multiple

8 (8.3%)

Liver metastasis size

< 5cm

14 (21.4%)

0.766

1.124

0.509-2.482

0.772

≥ 5cm

16 (12.5%)

Peritoneal metastasis

P1

5 (20.0%)

*0.007

3.836

1.292-11.383

*0.015

P0

25 (0)

Liver surgery

Lobectomy

23 (17.4%)

0.944

1.032

0.411-2.593

0.946

Partial hepatotrectomy

7 (14.3%)

T stage: n(%)

T1, T2

4 (50.0%)

0.508

0.757

0.324-1.767

0.519

T3, T4

26 (11.5%)

N metastasis: n(%)

Negative

7 (14.3%)

0.574

1.293

0.515-3.249

0.584

Positive

23 (17.4%)

Tumor embolus

Yes

13 (15.4%)

0.650

1.196

0.541-2.647

0.658

No

17 (17.6%)

Tumor differentiation

Well-intermediately differentiation

7 (28.6%)

0.379

1.535

0.573-4.112

0.394

Poorly differentiated

23 (13.0%)